Trial Profile
A phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of AMG 386 in adult patients with advanced solid tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2012
Price :
$35
*
At a glance
- Drugs Trebananib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Jun 2007 Status change from recruiting to completed.
- 20 Sep 2005 New trial record.